Abdulrahman Al-Mashdali: Targeted Therapies for CNS Involvement in CLL
Abdulrahman Al-Mashdali, Hematology Chief Fellow at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Therapeutic Advances in Hematology, adding:
”I’m pleased to share our newly published systematic review in Therapeutic Advances in Hematology:
‘Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review.’
CNS involvement in CLL/SLL is rare, diagnostically challenging, and historically associated with poor outcomes. In this systematic review, we analyzed 26 studies including 32 patients treated with novel targeted therapies.
Key findings:
- 94.1 percent overall response rate across 34 treatment regimens
- 55.9 percent complete responses and 38.2 percent partial responses
- Ibrutinib was the most frequently used targeted agent
- Venetoclax and ibrutinib–venetoclax combinations demonstrated encouraging activity
- Responses were observed even in patients with adverse biological features such as TP53 abnormalities, del(17p), and unmutated IGHV
While these findings are encouraging, the evidence remains largely based on case reports and small series. Prospective multicenter studies are needed to better define treatment sequencing, combination strategies, and the role of intrathecal therapy and radiotherapy.
I’m grateful to all my co-authors and colleagues who contributed to this work.”
Title: Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review
Authors: Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Raga M. Mukhtar, Shehab F. Mohamed,

Stay updated with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health